Copyright Reports & Markets. All rights reserved.

Global Familial Chylomicronemia Syndrome Therapeutics Market 2023 by Company, Regions, Type and Application, Forecast to 2029

Request for Sample of this report
Buy now

1 Market Overview

  • 1.1 Product Overview and Scope of Familial Chylomicronemia Syndrome Therapeutics
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Classification of Familial Chylomicronemia Syndrome Therapeutics by Type
    • 1.3.1 Overview: Global Familial Chylomicronemia Syndrome Therapeutics Market Size by Type: 2018 Versus 2022 Versus 2029
    • 1.3.2 Global Familial Chylomicronemia Syndrome Therapeutics Consumption Value Market Share by Type in 2022
    • 1.3.3 Dietary Supplements Familial Chylomicronemia Syndrome Therapeutics
    • 1.3.4 Gene Therapy Familial Chylomicronemia Syndrome Therapeutics
  • 1.4 Global Familial Chylomicronemia Syndrome Therapeutics Market by Application
    • 1.4.1 Overview: Global Familial Chylomicronemia Syndrome Therapeutics Market Size by Application: 2018 Versus 2022 Versus 2029
    • 1.4.2 Hospital Pharmacies
    • 1.4.3 Retail Pharmacies
    • 1.4.4 Others
  • 1.5 Global Familial Chylomicronemia Syndrome Therapeutics Market Size & Forecast
  • 1.6 Global Familial Chylomicronemia Syndrome Therapeutics Market Size and Forecast by Region
    • 1.6.1 Global Familial Chylomicronemia Syndrome Therapeutics Market Size by Region: 2018 VS 2022 VS 2029
    • 1.6.2 Global Familial Chylomicronemia Syndrome Therapeutics Market Size by Region, (2018-2029)
    • 1.6.3 North America Familial Chylomicronemia Syndrome Therapeutics Market Size and Prospect (2018-2029)
    • 1.6.4 Europe Familial Chylomicronemia Syndrome Therapeutics Market Size and Prospect (2018-2029)
    • 1.6.5 Asia-Pacific Familial Chylomicronemia Syndrome Therapeutics Market Size and Prospect (2018-2029)
    • 1.6.6 South America Familial Chylomicronemia Syndrome Therapeutics Market Size and Prospect (2018-2029)
    • 1.6.7 Middle East and Africa Familial Chylomicronemia Syndrome Therapeutics Market Size and Prospect (2018-2029)

2 Company Profiles

  • 2.1 Akcea Therapeutics
    • 2.1.1 Akcea Therapeutics Details
    • 2.1.2 Akcea Therapeutics Major Business
    • 2.1.3 Akcea Therapeutics Familial Chylomicronemia Syndrome Therapeutics Product and Solutions
    • 2.1.4 Akcea Therapeutics Familial Chylomicronemia Syndrome Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
    • 2.1.5 Akcea Therapeutics Recent Developments and Future Plans
  • 2.2 Ionis Pharmaceuticals
    • 2.2.1 Ionis Pharmaceuticals Details
    • 2.2.2 Ionis Pharmaceuticals Major Business
    • 2.2.3 Ionis Pharmaceuticals Familial Chylomicronemia Syndrome Therapeutics Product and Solutions
    • 2.2.4 Ionis Pharmaceuticals Familial Chylomicronemia Syndrome Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
    • 2.2.5 Ionis Pharmaceuticals Recent Developments and Future Plans
  • 2.3 uniQure N.V.
    • 2.3.1 uniQure N.V. Details
    • 2.3.2 uniQure N.V. Major Business
    • 2.3.3 uniQure N.V. Familial Chylomicronemia Syndrome Therapeutics Product and Solutions
    • 2.3.4 uniQure N.V. Familial Chylomicronemia Syndrome Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
    • 2.3.5 uniQure N.V. Recent Developments and Future Plans
  • 2.4 McKinsey & Company
    • 2.4.1 McKinsey & Company Details
    • 2.4.2 McKinsey & Company Major Business
    • 2.4.3 McKinsey & Company Familial Chylomicronemia Syndrome Therapeutics Product and Solutions
    • 2.4.4 McKinsey & Company Familial Chylomicronemia Syndrome Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
    • 2.4.5 McKinsey & Company Recent Developments and Future Plans
  • 2.5 Amgen Inc.
    • 2.5.1 Amgen Inc. Details
    • 2.5.2 Amgen Inc. Major Business
    • 2.5.3 Amgen Inc. Familial Chylomicronemia Syndrome Therapeutics Product and Solutions
    • 2.5.4 Amgen Inc. Familial Chylomicronemia Syndrome Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
    • 2.5.5 Amgen Inc. Recent Developments and Future Plans
  • 2.6 F. Hoffmann-La Roche Ltd
    • 2.6.1 F. Hoffmann-La Roche Ltd Details
    • 2.6.2 F. Hoffmann-La Roche Ltd Major Business
    • 2.6.3 F. Hoffmann-La Roche Ltd Familial Chylomicronemia Syndrome Therapeutics Product and Solutions
    • 2.6.4 F. Hoffmann-La Roche Ltd Familial Chylomicronemia Syndrome Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
    • 2.6.5 F. Hoffmann-La Roche Ltd Recent Developments and Future Plans
  • 2.7 Pfizer Inc.
    • 2.7.1 Pfizer Inc. Details
    • 2.7.2 Pfizer Inc. Major Business
    • 2.7.3 Pfizer Inc. Familial Chylomicronemia Syndrome Therapeutics Product and Solutions
    • 2.7.4 Pfizer Inc. Familial Chylomicronemia Syndrome Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
    • 2.7.5 Pfizer Inc. Recent Developments and Future Plans
  • 2.8 Novartis AG
    • 2.8.1 Novartis AG Details
    • 2.8.2 Novartis AG Major Business
    • 2.8.3 Novartis AG Familial Chylomicronemia Syndrome Therapeutics Product and Solutions
    • 2.8.4 Novartis AG Familial Chylomicronemia Syndrome Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
    • 2.8.5 Novartis AG Recent Developments and Future Plans
  • 2.9 Janssen Global Services, LLC
    • 2.9.1 Janssen Global Services, LLC Details
    • 2.9.2 Janssen Global Services, LLC Major Business
    • 2.9.3 Janssen Global Services, LLC Familial Chylomicronemia Syndrome Therapeutics Product and Solutions
    • 2.9.4 Janssen Global Services, LLC Familial Chylomicronemia Syndrome Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
    • 2.9.5 Janssen Global Services, LLC Recent Developments and Future Plans
  • 2.10 AMAG Pharmaceuticals
    • 2.10.1 AMAG Pharmaceuticals Details
    • 2.10.2 AMAG Pharmaceuticals Major Business
    • 2.10.3 AMAG Pharmaceuticals Familial Chylomicronemia Syndrome Therapeutics Product and Solutions
    • 2.10.4 AMAG Pharmaceuticals Familial Chylomicronemia Syndrome Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
    • 2.10.5 AMAG Pharmaceuticals Recent Developments and Future Plans
  • 2.11 Teva Pharmaceutical Industries Ltd
    • 2.11.1 Teva Pharmaceutical Industries Ltd Details
    • 2.11.2 Teva Pharmaceutical Industries Ltd Major Business
    • 2.11.3 Teva Pharmaceutical Industries Ltd Familial Chylomicronemia Syndrome Therapeutics Product and Solutions
    • 2.11.4 Teva Pharmaceutical Industries Ltd Familial Chylomicronemia Syndrome Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
    • 2.11.5 Teva Pharmaceutical Industries Ltd Recent Developments and Future Plans
  • 2.12 Rockwell Medical
    • 2.12.1 Rockwell Medical Details
    • 2.12.2 Rockwell Medical Major Business
    • 2.12.3 Rockwell Medical Familial Chylomicronemia Syndrome Therapeutics Product and Solutions
    • 2.12.4 Rockwell Medical Familial Chylomicronemia Syndrome Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
    • 2.12.5 Rockwell Medical Recent Developments and Future Plans
  • 2.13 Vifor Pharma Management Ltd.
    • 2.13.1 Vifor Pharma Management Ltd. Details
    • 2.13.2 Vifor Pharma Management Ltd. Major Business
    • 2.13.3 Vifor Pharma Management Ltd. Familial Chylomicronemia Syndrome Therapeutics Product and Solutions
    • 2.13.4 Vifor Pharma Management Ltd. Familial Chylomicronemia Syndrome Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
    • 2.13.5 Vifor Pharma Management Ltd. Recent Developments and Future Plans
  • 2.14 Akebia Therapeutics.
    • 2.14.1 Akebia Therapeutics. Details
    • 2.14.2 Akebia Therapeutics. Major Business
    • 2.14.3 Akebia Therapeutics. Familial Chylomicronemia Syndrome Therapeutics Product and Solutions
    • 2.14.4 Akebia Therapeutics. Familial Chylomicronemia Syndrome Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
    • 2.14.5 Akebia Therapeutics. Recent Developments and Future Plans

3 Market Competition, by Players

  • 3.1 Global Familial Chylomicronemia Syndrome Therapeutics Revenue and Share by Players (2018-2023)
  • 3.2 Market Share Analysis (2022)
    • 3.2.1 Market Share of Familial Chylomicronemia Syndrome Therapeutics by Company Revenue
    • 3.2.2 Top 3 Familial Chylomicronemia Syndrome Therapeutics Players Market Share in 2022
    • 3.2.3 Top 6 Familial Chylomicronemia Syndrome Therapeutics Players Market Share in 2022
  • 3.3 Familial Chylomicronemia Syndrome Therapeutics Market: Overall Company Footprint Analysis
    • 3.3.1 Familial Chylomicronemia Syndrome Therapeutics Market: Region Footprint
    • 3.3.2 Familial Chylomicronemia Syndrome Therapeutics Market: Company Product Type Footprint
    • 3.3.3 Familial Chylomicronemia Syndrome Therapeutics Market: Company Product Application Footprint
  • 3.4 New Market Entrants and Barriers to Market Entry
  • 3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type

  • 4.1 Global Familial Chylomicronemia Syndrome Therapeutics Consumption Value and Market Share by Type (2018-2023)
  • 4.2 Global Familial Chylomicronemia Syndrome Therapeutics Market Forecast by Type (2024-2029)

5 Market Size Segment by Application

  • 5.1 Global Familial Chylomicronemia Syndrome Therapeutics Consumption Value Market Share by Application (2018-2023)
  • 5.2 Global Familial Chylomicronemia Syndrome Therapeutics Market Forecast by Application (2024-2029)

6 North America

  • 6.1 North America Familial Chylomicronemia Syndrome Therapeutics Consumption Value by Type (2018-2029)
  • 6.2 North America Familial Chylomicronemia Syndrome Therapeutics Consumption Value by Application (2018-2029)
  • 6.3 North America Familial Chylomicronemia Syndrome Therapeutics Market Size by Country
    • 6.3.1 North America Familial Chylomicronemia Syndrome Therapeutics Consumption Value by Country (2018-2029)
    • 6.3.2 United States Familial Chylomicronemia Syndrome Therapeutics Market Size and Forecast (2018-2029)
    • 6.3.3 Canada Familial Chylomicronemia Syndrome Therapeutics Market Size and Forecast (2018-2029)
    • 6.3.4 Mexico Familial Chylomicronemia Syndrome Therapeutics Market Size and Forecast (2018-2029)

7 Europe

  • 7.1 Europe Familial Chylomicronemia Syndrome Therapeutics Consumption Value by Type (2018-2029)
  • 7.2 Europe Familial Chylomicronemia Syndrome Therapeutics Consumption Value by Application (2018-2029)
  • 7.3 Europe Familial Chylomicronemia Syndrome Therapeutics Market Size by Country
    • 7.3.1 Europe Familial Chylomicronemia Syndrome Therapeutics Consumption Value by Country (2018-2029)
    • 7.3.2 Germany Familial Chylomicronemia Syndrome Therapeutics Market Size and Forecast (2018-2029)
    • 7.3.3 France Familial Chylomicronemia Syndrome Therapeutics Market Size and Forecast (2018-2029)
    • 7.3.4 United Kingdom Familial Chylomicronemia Syndrome Therapeutics Market Size and Forecast (2018-2029)
    • 7.3.5 Russia Familial Chylomicronemia Syndrome Therapeutics Market Size and Forecast (2018-2029)
    • 7.3.6 Italy Familial Chylomicronemia Syndrome Therapeutics Market Size and Forecast (2018-2029)

8 Asia-Pacific

  • 8.1 Asia-Pacific Familial Chylomicronemia Syndrome Therapeutics Consumption Value by Type (2018-2029)
  • 8.2 Asia-Pacific Familial Chylomicronemia Syndrome Therapeutics Consumption Value by Application (2018-2029)
  • 8.3 Asia-Pacific Familial Chylomicronemia Syndrome Therapeutics Market Size by Region
    • 8.3.1 Asia-Pacific Familial Chylomicronemia Syndrome Therapeutics Consumption Value by Region (2018-2029)
    • 8.3.2 China Familial Chylomicronemia Syndrome Therapeutics Market Size and Forecast (2018-2029)
    • 8.3.3 Japan Familial Chylomicronemia Syndrome Therapeutics Market Size and Forecast (2018-2029)
    • 8.3.4 South Korea Familial Chylomicronemia Syndrome Therapeutics Market Size and Forecast (2018-2029)
    • 8.3.5 India Familial Chylomicronemia Syndrome Therapeutics Market Size and Forecast (2018-2029)
    • 8.3.6 Southeast Asia Familial Chylomicronemia Syndrome Therapeutics Market Size and Forecast (2018-2029)
    • 8.3.7 Australia Familial Chylomicronemia Syndrome Therapeutics Market Size and Forecast (2018-2029)

9 South America

  • 9.1 South America Familial Chylomicronemia Syndrome Therapeutics Consumption Value by Type (2018-2029)
  • 9.2 South America Familial Chylomicronemia Syndrome Therapeutics Consumption Value by Application (2018-2029)
  • 9.3 South America Familial Chylomicronemia Syndrome Therapeutics Market Size by Country
    • 9.3.1 South America Familial Chylomicronemia Syndrome Therapeutics Consumption Value by Country (2018-2029)
    • 9.3.2 Brazil Familial Chylomicronemia Syndrome Therapeutics Market Size and Forecast (2018-2029)
    • 9.3.3 Argentina Familial Chylomicronemia Syndrome Therapeutics Market Size and Forecast (2018-2029)

10 Middle East & Africa

  • 10.1 Middle East & Africa Familial Chylomicronemia Syndrome Therapeutics Consumption Value by Type (2018-2029)
  • 10.2 Middle East & Africa Familial Chylomicronemia Syndrome Therapeutics Consumption Value by Application (2018-2029)
  • 10.3 Middle East & Africa Familial Chylomicronemia Syndrome Therapeutics Market Size by Country
    • 10.3.1 Middle East & Africa Familial Chylomicronemia Syndrome Therapeutics Consumption Value by Country (2018-2029)
    • 10.3.2 Turkey Familial Chylomicronemia Syndrome Therapeutics Market Size and Forecast (2018-2029)
    • 10.3.3 Saudi Arabia Familial Chylomicronemia Syndrome Therapeutics Market Size and Forecast (2018-2029)
    • 10.3.4 UAE Familial Chylomicronemia Syndrome Therapeutics Market Size and Forecast (2018-2029)

11 Market Dynamics

  • 11.1 Familial Chylomicronemia Syndrome Therapeutics Market Drivers
  • 11.2 Familial Chylomicronemia Syndrome Therapeutics Market Restraints
  • 11.3 Familial Chylomicronemia Syndrome Therapeutics Trends Analysis
  • 11.4 Porters Five Forces Analysis
    • 11.4.1 Threat of New Entrants
    • 11.4.2 Bargaining Power of Suppliers
    • 11.4.3 Bargaining Power of Buyers
    • 11.4.4 Threat of Substitutes
    • 11.4.5 Competitive Rivalry
  • 11.5 Influence of COVID-19 and Russia-Ukraine War
    • 11.5.1 Influence of COVID-19
    • 11.5.2 Influence of Russia-Ukraine War

12 Industry Chain Analysis

  • 12.1 Familial Chylomicronemia Syndrome Therapeutics Industry Chain
  • 12.2 Familial Chylomicronemia Syndrome Therapeutics Upstream Analysis
  • 12.3 Familial Chylomicronemia Syndrome Therapeutics Midstream Analysis
  • 12.4 Familial Chylomicronemia Syndrome Therapeutics Downstream Analysis

13 Research Findings and Conclusion

    14 Appendix

    • 14.1 Methodology
    • 14.2 Research Process and Data Source

    According to our (Global Info Research) latest study, the global Familial Chylomicronemia Syndrome Therapeutics market size was valued at USD million in 2022 and is forecast to a readjusted size of USD million by 2029 with a CAGR of % during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
    This report is a detailed and comprehensive analysis for global Familial Chylomicronemia Syndrome Therapeutics market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.
    Key Features:
    Global Familial Chylomicronemia Syndrome Therapeutics market size and forecasts, in consumption value ($ Million), 2018-2029
    Global Familial Chylomicronemia Syndrome Therapeutics market size and forecasts by region and country, in consumption value ($ Million), 2018-2029
    Global Familial Chylomicronemia Syndrome Therapeutics market size and forecasts, by Type and by Application, in consumption value ($ Million), 2018-2029
    Global Familial Chylomicronemia Syndrome Therapeutics market shares of main players, in revenue ($ Million), 2018-2023
    The Primary Objectives in This Report Are:
    To determine the size of the total market opportunity of global and key countries
    To assess the growth potential for Familial Chylomicronemia Syndrome Therapeutics
    To forecast future growth in each product and end-use market
    To assess competitive factors affecting the marketplace
    This report profiles key players in the global Familial Chylomicronemia Syndrome Therapeutics market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Akcea Therapeutics, Ionis Pharmaceuticals, uniQure N.V., McKinsey & Company and Amgen Inc., etc.
    This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
    Market segmentation
    Familial Chylomicronemia Syndrome Therapeutics market is split by Type and by Application. For the period 2018-2029, the growth among segments provide accurate calculations and forecasts for consumption value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
    Market segment by Type
    Dietary Supplements Familial Chylomicronemia Syndrome Therapeutics
    Gene Therapy Familial Chylomicronemia Syndrome Therapeutics
    Market segment by Application
    Hospital Pharmacies
    Retail Pharmacies
    Others
    Market segment by players, this report covers
    Akcea Therapeutics
    Ionis Pharmaceuticals
    uniQure N.V.
    McKinsey & Company
    Amgen Inc.
    F. Hoffmann-La Roche Ltd
    Pfizer Inc.
    Novartis AG
    Janssen Global Services, LLC
    AMAG Pharmaceuticals
    Teva Pharmaceutical Industries Ltd
    Rockwell Medical
    Vifor Pharma Management Ltd.
    Akebia Therapeutics.
    Market segment by regions, regional analysis covers
    North America (United States, Canada, and Mexico)
    Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
    South America (Brazil, Argentina and Rest of South America)
    Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
    The content of the study subjects, includes a total of 13 chapters:
    Chapter 1, to describe Familial Chylomicronemia Syndrome Therapeutics product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top players of Familial Chylomicronemia Syndrome Therapeutics, with revenue, gross margin and global market share of Familial Chylomicronemia Syndrome Therapeutics from 2018 to 2023.
    Chapter 3, the Familial Chylomicronemia Syndrome Therapeutics competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
    Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2018 to 2029.
    Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2018 to 2023.and Familial Chylomicronemia Syndrome Therapeutics market forecast, by regions, type and application, with consumption value, from 2024 to 2029.
    Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War
    Chapter 12, the key raw materials and key suppliers, and industry chain of Familial Chylomicronemia Syndrome Therapeutics.
    Chapter 13, to describe Familial Chylomicronemia Syndrome Therapeutics research findings and conclusion.

    Buy now